Outcomes of ixazomib/lenalidomide/dexamethasone for multiple myeloma: A multicenter retrospective analysis.

Teruhito TakakuwaRyosuke YamamuraKensuke OhtaHitomi KanekoKazunori Imada Aya NakayaShin-Ichi FuchidaHirohiko ShibayamaMitsuhiro MatsudaYutaka ShimazuYoko AdachiSatoru KosugiHitoji UchiyamaHirokazu TanakaHitoshi HanamotoYuji ShimuraJunya KandaYoshiyuki OndaNobuhiko UoshimaHideo YagiSatoshi YoshiharaMasayuki HinoChihiro ShimazakiAkifumi Takaori-KondoJunya KurodaItaru MatsumuraYuzuru KanakuraShosaku Nomura

Published in: European journal of haematology (2021)

This study presents the largest real-world data of patients treated with IRd in Asia. However, in real clinical practice, the patient background is different from the TOURMALINE-MM1 study, and IRd showed poor efficacy, especially in the non-IgG type and lenalidomide-refractory patients with RRMM.

Keyphrases

multiple myeloma
clinical practice
low dose
type diabetes
clinical trial
machine learning
electronic health record
case report
adipose tissue
weight loss
data analysis